The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Identification of preexisting adaptive immunity to Cas9 proteins in humans
Open accessPublished version of a preprint
Abstract
The CRISPR-Cas9 system is a powerful tool for genome editing, which allows the precise modification of specific DNA sequences. Many efforts are underway to use the CRISPR-Cas9 system to therapeutically correct human genetic diseases 1-6. The most widely used orthologs of Cas9 are derived from Staphylococcus aureus and Streptococcus pyogenes 5,7. Given that these two bacterial species infect the human population at high frequencies 8,9, we hypothesized that humans may harbor preexisting adaptive immune responses to the Cas9 orthologs derived from these bacterial species, SaCas9 (S. aureus) and SpCas9 (S. pyogenes). By probing human serum for the presence of anti-Cas9 antibodies using an enzyme-linked immunosorbent assay, we detected antibodies against both SaCas9 and SpCas9 in 78% and 58% of donors, respectively. We also found anti-SaCas9 T cells in 78% and anti-SpCas9 T cells in 67% of donors, which demonstrates a high prevalence of antigen-specific T cells against both orthologs. We confirmed that these T cells were Cas9-specific by demonstrating a Cas9-specific cytokine response following isolation, expansion, and antigen restimulation. Together, these data demonstrate that there are preexisting humoral and cell-mediated adaptive immune responses to Cas9 in humans, a finding that should be taken into account as the CRISPR-Cas9 system moves toward clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Second, long-term expression of genome editing molecules may expose patients to undesired off-target editing or immune reactions 66,67 .”
From The promise and challenge of therapeutic genome editing (2020) · cites this paper as [66]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Pre-existing Cas9 antibodies and reactive T-cells have been detected in humans exposed to pathogenic bacteria harboring CRISPR systems, although it is unknown whether these are present at concentrations sufficient to trigger an immune response to the genome editing enzymes 66,104 .”
From The promise and challenge of therapeutic genome editing (2020) · cites this paper as [66]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“although it is unknown whether these are present at concentrations sufficient to trigger an immune response to the genome editing enzymes 66,104 .”
From The promise and challenge of therapeutic genome editing (2020) · cites this paper as [66]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Other factors affecting clinical applications of genome editing include the immunogenicity of bacterially-derived editing proteins, the potential for pre-existing antibodies against CRISPR components to cause inflammation and the unknown long-term safety and stability of genome editing outcomes.”
From The promise and challenge of therapeutic genome editing (2020) · cites this paper as [66]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Another consideration for CRISPR/Cas9-based systems for retinal gene editing is the potential for a heightened adaptive immune response given the bacterial origin of the Cas9 enzyme and high prevalence of pre-existing immunity (Charlesworth et al., 2019).”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Charlesworth et al., 2019
In the citing paper
“A study involving 125 healthy adult human blood donors in the USA with a median age of 43 reported pre-existing anti-SaCas9 antibodies and anti-SpCas9 antibodies in 78% and 58% of the total samples, respectively.”
From Immune responses to gene editing by viral and non-viral delivery vectors used in retinal gene therapy (2022) · cites this paper as [24]
In the citing paper
“Among the tested donors, 78% had SaCas9-specific T-cells and 67% were positive for SpCas9-specific T-cells.”
From Immune responses to gene editing by viral and non-viral delivery vectors used in retinal gene therapy (2022) · cites this paper as [24]
In the citing paper
“While there are discrepancies regarding the exact prevalence of these antibodies in humans, a majority of the general population may exhibit preexisting α-Cas93.”
From Investigation of Cas9 Antibodies in the Human Eye (2022) · cites this paper as [3]
In the citing paper
“Furthermore, a high prevalence of preexisting cellular immunity against Cas9 (Cas9-reactive T-cells) has also been identified2–4.”
From Investigation of Cas9 Antibodies in the Human Eye (2022) · cites this paper as [3]
In the citing paper
“multiple groups have reported high frequencies (>60% of patients) of Cas9 reactive T-cells in humans2–4.”
From Investigation of Cas9 Antibodies in the Human Eye (2022) · cites this paper as [3]
In the citing paper
“This may explain the lower raw ELISA A450 values we observed compared with previous work (Table 1)3.”
From Investigation of Cas9 Antibodies in the Human Eye (2022) · cites this paper as [3]
In the citing paper
“CRISPR-Cas9 is a promising therapeutic tool that allows genetic target-specific cleavage and editing (111).”
From Immunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies (2021) · cites this paper as [111]
In the citing paper
“One concern is that the prevalence of anti-SaCas9 antibodies and T-cell in humans are reported to be 78% (111).”
From Immunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies (2021) · cites this paper as [111]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
Staphylococcus aureus Infections
Lowy, F. D. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808203390806 · Cited by 6,018
In vivo genome editing using Staphylococcus aureus Cas9
Ran, F. A., Cong, L., Yan, W. X., Scott, D. A., Gootenberg, J. S., Kriz, A. J., Zetsche, B., Shalem, O., Wu, X., Makarova, K. S., et al. (2015) · Nature · doi:10.1038/nature14299 · Cited by 2,687
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection
Eyquem, J., Mansilla-Soto, J., Giavridis, T., van der Stegen, S. J. C., Hamieh, M., Cunanan, K. M., Odak, A., Gönen, M., & Sadelain, M. (2017) · Nature · doi:10.1038/nature21405 · Cited by 1,831
Zuris, J. A., Thompson, D. B., Shu, Y., Guilinger, J. P., Bessen, J. L., Hu, J. H., Maeder, M. L., Joung, J. K., Chen, Z.-Y., & Liu, D. R. (2015) · Nature Biotechnology · doi:10.1038/nbt.3081 · Cited by 1,460
In vivo genome editing via CRISPR/Cas9 mediated homology-independent targeted integration
Suzuki, K., Tsunekawa, Y., Hernandez-Benitez, R., Wu, J., Zhu, J., Kim, E. J., Hatanaka, F., Yamamoto, M., Araoka, T., Li, Z., et al. (2016) · Nature · doi:10.1038/nature20565 · Cited by 1,150
In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy
Nelson, C. E., Hakim, C. H., Ousterout, D. G., Thakore, P. I., Moreb, E. A., Rivera, R. M. C., Madhavan, S., Pan, X., Ran, F. A., Yan, W. X., et al. (2016) · Science · doi:10.1126/science.aad5143 · Cited by 1,144
Pukelsheim, F. (1994) · The American Statistician · doi:10.1080/00031305.1994.10476030 · Cited by 1,072
Cited by
Sorted by citations
Car t cell immunotherapy for human cancer
June, C. H., O’Connor, R. S., Kawalekar, O. U., Ghassemi, S., & Milone, M. C. (2018) · Science · doi:10.1126/science.aar6711 · Cited by 3,207
Li, H., Yang, Y., Hong, W., Huang, M., Wu, M., & Zhao, X. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0089-y · Cited by 1,829
The CRISPR tool kit for genome editing and beyond
Adli, M. (2018) · Nature Communications · doi:10.1038/s41467-018-04252-2 · Cited by 1,545
CRISPR-engineered T cells in patients with refractory cancer
Stadtmauer, E. A., Fraietta, J. A., Davis, M. M., Cohen, A. D., Weber, K. L., Lancaster, E., Mangan, P. A., Kulikovskaya, I., Gupta, M., Chen, F., et al. (2020) · Science · doi:10.1126/science.aba7365 · Cited by 1,478
The next generation of CRISPR–Cas technologies and applications
Pickar-Oliver, A., & Gersbach, C. A. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0131-5 · Cited by 1,459
CRISPR-Cas guides the future of genetic engineering
Knott, G. J., & Doudna, J. A. (2018) · Science · doi:10.1126/science.aat5011 · Cited by 1,410
The promise and challenge of therapeutic genome editing
Doudna, J. A. (2020) · Nature · doi:10.1038/s41586-020-1978-5 · Cited by 1,126
CRISPR technology: A decade of genome editing is only the beginning
Wang, J. Y., & Doudna, J. A. (2023) · Science · doi:10.1126/science.add8643 · Cited by 1,105
Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges
Martin, J. D., Cabral, H., Stylianopoulos, T., & Jain, R. K. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0308-z · Cited by 691
Past, present, and future of CRISPR genome editing technologies
Pacesa, M., Pelea, O., & Jinek, M. (2024) · Cell · doi:10.1016/j.cell.2024.01.042 · Cited by 609
CRISPR Gene Therapy: Applications, Limitations, and Implications for the Future
Uddin, F. Z., Rudin, C. M., & Sen, T. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01387 · Cited by 641
Hurtado, S., Milem, J. F., Clayton-Pedersen, A. R., & Allen, W. R. (1999) · Cited by 568
Therapeutic in vivo delivery of gene editing agents
Raguram, A., Banskota, S., & Liu, D. R. (2022) · Cell · doi:10.1016/j.cell.2022.03.045 · Cited by 552
CRISPR-Based Therapeutic Genome Editing: Strategies and In Vivo Delivery by AAV Vectors
Wang, D., Zhang, F., & Gao, G. (2020) · Cell · doi:10.1016/j.cell.2020.03.023 · Cited by 539
CRISPR-Cas9 DNA Base-Editing and Prime-Editing
Kantor, A., McClements, M., & MacLaren, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176240 · Cited by 462
Mechanism and Applications of CRISPR/Cas-9-Mediated Genome Editing
Mengstie, M. A., & Wondimu, B. Z. (2021) · Biologics: Targets and Therapy · doi:10.2147/btt.s326422 · Cited by 478
Base editing: advances and therapeutic opportunities
Porto, E. M., Komor, A. C., Slaymaker, I. M., & Yeo, G. W.-M. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0084-6 · Cited by 499
Engineering the next generation of cell-based therapeutics
Bashor, C. J., Hilton, I. B., Bandukwala, H. S., Smith, D. M., & Omid Veiseh, A. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00476-6 · Cited by 472
CRISPR in cancer biology and therapy
Katti, A., Diaz, B. J., Caragine, C. M., Sanjana, N. E., & Dow, L. E. (2022) · Nature reviews. Cancer · doi:10.1038/s41568-022-00441-w · Cited by 457
Long-term evaluation of AAV-CRISPR genome editing for Duchenne muscular dystrophy
Nelson, C. E., Wu, Y., Gemberling, M. P., Oliver, M. L., Waller, M. A., Bohning, J. D., Robinson-Hamm, J. N., Bulaklak, K., Rivera, R. M. C., Collier, J. H., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0344-3 · Cited by 444
Xu, Y., & Li, Z. (2020) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2020.08.031 · Cited by 457
Engineered miniature CRISPR-Cas system for mammalian genome regulation and editing
Xu, X., Chemparathy, A. G., Zeng, L., Kempton, H. R., Shang, S., Nakamura, M., & Qi, L. S. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.08.008 · Cited by 411
High prevalence of Streptococcus pyogenes Cas9-reactive T cells within the adult human population
Wagner, D. L., Amini, L., Wendering, D. J., Burkhardt, L.-M., Akyüz, L., Reinke, P., Volk, H.-D., & Schmueck-Henneresse, M. (2019) · Nature Medicine · doi:10.1038/s41591-018-0204-6 · Cited by 399
Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy
Gong, Y., Klein Wolterink, R. G. J., Wang, J., Bos, G. M. J., & Germeraad, W. T. V. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01083-5 · Cited by 379
Therapeutic AAV Gene Transfer to the Nervous System: A Clinical Reality
Hudry, E., & Vandenberghe, L. H. (2019) · Neuron · doi:10.1016/j.neuron.2019.02.017 · Cited by 383
Immunogenicity of CAR T cells in cancer therapy
Wagner, D. L., Fritsche, E., Pulsipher, M. A., Ahmed, N. M., Hamieh, M., Hegde, M. G., Ruella, M., Savoldo, B., Shah, N. N., Turtle, C. J., et al. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00476-2 · Cited by 318
Gene therapy for neurological disorders: progress and prospects
Deverman, B. E., Ravina, B. M., Bankiewicz, K. S., Paul, S. M., & Sah, D. W. Y. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.110 · Cited by 306
Delivery Aspects of CRISPR/Cas for in Vivo Genome Editing
Wilbie, D., Walther, J., & Mastrobattista, E. (2019) · Accounts of Chemical Research · doi:10.1021/acs.accounts.9b00106 · Cited by 311
Programmable RNA editing by recruiting endogenous ADAR using engineered RNAs
Qu, L., Yi, Z., Zhu, S., Wang, C., Cao, Z., Zhou, Z. L., Yuan, P., Yu, Y. F., Tian, F., Liu, Z., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0178-z · Cited by 292
CRISPR technologies and the search for the PAM-free nuclease
Collias, D., & Beisel, C. L. (2021) · Nature Communications · doi:10.1038/s41467-020-20633-y · Cited by 304
The delivery challenge: fulfilling the promise of therapeutic genome editing
van Haasteren, J., Li, J., Scheideler, O. J., Murthy, N., & Schaffer, D. V. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0565-5 · Cited by 285
Wang, H.-X., Song, Z., Lao, Y.-H., Xu, X., Gong, J., Cheng, D., Chakraborty, S., Park, J. S., Li, M., Huang, D., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1712963115 · Cited by 277
Delivery of CRISPR-Cas tools for in vivo genome editing therapy: Trends and challenges
Taha, E. A., Lee, J., & Hotta, A. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.01.013 · Cited by 259
Cas9 immunity creates challenges for CRISPR gene editing therapies
Crudele, J. M., & Chamberlain, J. S. (2018) · Nature Communications · doi:10.1038/s41467-018-05843-9 · Cited by 259
Zhang, H., Qin, C., An, C., Zheng, X., Wen, S., Chen, W., Liu, X., Lv, Z., Yang, P., Xu, W., et al. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01431-6 · Cited by 264
Erratum: Gene therapy for neurological disorders: progress and prospects
Deverman, B. E., Ravina, B. M., Bankiewicz, K. S., Paul, S. M., & Sah, D. W. Y. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.158 · Cited by 248
Prevalence of Pre-existing Antibodies to CRISPR-Associated Nuclease Cas9 in the USA Population
Simhadri, V. L., McGill, J., McMahon, S., Wang, J., Jiang, H., & Sauna, Z. E. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.06.006 · Cited by 241
Frequent aneuploidy in primary human T cells after CRISPR–Cas9 cleavage
Nahmad, A. D., Reuveni, E., Goldschmidt, E., Tenne, T., Liberman, M., Horovitz‐Fried, M., Khosravi, R., Kobo, H., Reinstein, E., Madi, A., et al. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01377-0 · Cited by 246
Bioethical issues in genome editing by CRISPR-Cas9 technology
Ayanoğlu, F. B., ELÇİN, A. E., & Elçin, Y. M. (2020) · TURKISH JOURNAL OF BIOLOGY · doi:10.3906/biy-1912-52 · Cited by 246
AAV-CRISPR Gene Editing Is Negated by Pre-existing Immunity to Cas9
Li, A., Tanner, M. R., Lee, C. M., Hurley, A. E., De Giorgi, M., Jarrett, K. E., Davis, T. H., Doerfler, A. M., Bao, G., Beeton, C., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.04.017 · Cited by 230
A New Class of Medicines through DNA Editing
Porteus, M. H. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1800729 · Cited by 229
Self-citationIn vivo delivery of CRISPR-Cas9 therapeutics: Progress and challenges
Behr, M., Zhou, J., Xu, B., & Zhang, H. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.05.020 · Cited by 210
Exosome-mediated delivery of CRISPR/Cas9 for targeting of oncogenic Kras G12D in pancreatic cancer
McAndrews, K. M., Xiao, F., Chronopoulos, A., LeBleu, V. S., Kugeratski, F. G., & Kalluri, R. (2021) · Life Science Alliance · doi:10.26508/lsa.202000875 · Cited by 216
Delivery of CRISPR/Cas systems for cancer gene therapy and immunotherapy
Song, X., Liu, C., Wang, N., Huang, H., He, S., Gong, C., & Wei, Y. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.04.010 · Cited by 217
Recent advances in the CRISPR genome editing tool set
Moon, S. B., Kim, D. Y., Ko, J., & Kim, Y.-S. (2019) · Experimental & Molecular Medicine · doi:10.1038/s12276-019-0339-7 · Cited by 214
Engineered materials for in vivo delivery of genome-editing machinery
Tong, S., Moyo, B., Lee, C. M., Leong, K. W., & Bao, G. (2019) · Nature Reviews Materials · doi:10.1038/s41578-019-0145-9 · Cited by 208
Gene editing and CRISPR in the clinic: current and future perspectives
Hirakawa, M. P., Krishnakumar, R., Timlin, J. A., Carney, J. P., & Butler, K. S. (2020) · Bioscience Reports · doi:10.1042/bsr20200127 · Cited by 207
CRISPR-Cas Tools and Their Application in Genetic Engineering of Human Stem Cells and Organoids
Hendriks, D. F. G., Clevers, H. C., & Artegiani, B. (2020) · Cell stem cell · doi:10.1016/j.stem.2020.10.014 · Cited by 202
Spatiotemporal control of CRISPR/Cas9 gene editing
Zhuo, C., Zhang, J., Lee, J., Jiao, J., Cheng, D., Liu, L., Kim, H., Tao, Y., & Li, M. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00645-w · Cited by 196
Rui, Y., Wilson, D. R., Choi, J. H., Varanasi, M., Sanders, K., Karlsson, J. E., Lim, M. K., & Green, J. J. (2019) · Science Advances · doi:10.1126/sciadv.aay3255 · Cited by 196
Early and late stage gene therapy interventions for inherited retinal degenerations
Botto, C., Rucli, M., Tekinsoy, M. D., Pulman, J., Sahel, J.-A., & Dalkara, D. (2022) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2021.100975 · Cited by 190
A High-Throughput Platform to Identify Small-Molecule Inhibitors of CRISPR-Cas9
Maji, B., Gangopadhyay, S. A., Lee, M., Shi, M., Wu, P., Heler, R., Mok, B. Y., Lim, D., Siriwardena, S. U., Paul, B., et al. (2019) · Cell · doi:10.1016/j.cell.2019.04.009 · Cited by 189
Immunogenicity of Cas9 Protein
Mehta, A., & Merkel, O. M. (2019) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2019.10.003 · Cited by 192
Development of CRISPR-Cas systems for genome editing and beyond
Zhang, F. (2019) · Quarterly Reviews of Biophysics · doi:10.1017/s0033583519000052 · Cited by 188
Rational designs of in vivo CRISPR-Cas delivery systems
Xu, C., Chen, G., Luo, Y., Zhang, Y., Zhao, G., Lu, Z.-D., Czarna, A., Gu, Z., & Wang, J. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.11.005 · Cited by 187
Yi, Z., Qu, L., Tang, H., Liu, Z., Liu, Y., Tian, F., Wang, C., Zhang, X., Feng, Z., Yu, Y. F., et al. (2022) · Nature Biotechnology · doi:10.1038/s41587-021-01180-3 · Cited by 190
Application of CRISPR/Cas9-Based Gene Editing in HIV-1/AIDS Therapy
Xiao, Q., Guo, D., & Chen, S. (2019) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2019.00069 · Cited by 193
Applications and challenges of CRISPR-Cas gene-editing to disease treatment in clinics
Liu, W., Li, L., Jiang, J., Wu, M., & Lin, P. (2021) · Precision Clinical Medicine · doi:10.1093/pcmedi/pbab014 · Cited by 196
Zhang, B. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.30064 · Cited by 191
Rasul, M. F., Hussen, B. M., Salihi, A. B., Ismael, B. S., Jalal, P. J., Zanichelli, A., Jamali, E., Baniahmad, A., Ghafouri‐Fard, S., Basiri, A., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01487-4 · Cited by 187
PTEN-opathies: from biological insights to evidence-based precision medicine
Yehia, L., Ngeow, J. Y. Y., & Eng, C. (2019) · Journal of Clinical Investigation · doi:10.1172/jci121277 · Cited by 178
CRISPR–Cas: a tool for cancer research and therapeutics
Yin, H., Xue, W., & Anderson, D. G. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0166-8 · Cited by 185
Drug delivery systems for CRISPR-based genome editors
Madigan, V. J., Zhang, F., & Dahlman, J. E. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00762-x · Cited by 193
Multidimensional control of therapeutic human cell function with synthetic gene circuits
Li, H.-S., Israni, D. V., Gagnon, K. A., Gan, K. A., Raymond, M. H., Sander, J. D., Roybal, K. T., Joung, J. K., Wong, W. W., & Khalil, A. S. (2022) · Science · doi:10.1126/science.ade0156 · Cited by 187
Hakim, C. H., Kumar, S. R. P., Pérez-López, D. O., Wasala, N. B., Zhang, D., Yue, Y., Teixeira, J., Pan, X., Zhang, K., Million, E. D., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26830-7 · Cited by 175
In utero nanoparticle delivery for site-specific genome editing
Ricciardi, A. S., Bahal, R., Farrelly, J. S., Quijano, E., Bianchi, A. H., Luks, V. L., Putman, R., López‐Giráldez, F., Coşkun, S., Song, E., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04894-2 · Cited by 176
RNA editing: Expanding the potential of RNA therapeutics
Booth, B. J., Nourreddine, S., Katrekar, D., Savva, Y., Bose, D., Long, T. J., Huss, D. J., & Mali, P. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.01.005 · Cited by 171
Covalently closed circular DNA: The ultimate therapeutic target for curing HBV infections
Martínez, M. G., Boyd, A. C., Combe, E., Testoni, B., & Zoulim, F. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.05.013 · Cited by 172
A SARS-CoV-2 targeted siRNA-nanoparticle therapy for COVID-19
Idris, A., Davis, A. M., Supramaniam, A., Acharya, D., Kelly, G., Tayyar, Y., West, N. P., Zhang, P., McMillan, C. L. D., Soemardy, C., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.05.004 · Cited by 167
Programmable RNA-Guided RNA Effector Proteins Built from Human Parts
Rauch, S., He, E., Srienc, M., Zhou, H., Zhang, Z. S., & Dickinson, B. C. (2019) · Cell · doi:10.1016/j.cell.2019.05.049 · Cited by 163
Zhang, Y., Li, H. Z., Min, Y.-L., Sanchez‐Ortiz, E., Huang, J. H., Mireault, A. A., Shelton, J. M., Kim, J., Mammen, P. P. A., Bassel‐Duby, R., et al. (2020) · Science Advances · doi:10.1126/sciadv.aay6812 · Cited by 165
CRISPR/Cas: Advances, Limitations, and Applications for Precision Cancer Research
Yang, Y., Xu, J., Ge, S., & Lai, L. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.649896 · Cited by 167
Characterization and mitigation of gene expression burden in mammalian cells
Frei, T., Cella, F., Tedeschi, F., Gutiérrez, J., Stan, G.-B. V., Khammash, M., & Siciliano, V. (2020) · Nature Communications · doi:10.1038/s41467-020-18392-x · Cited by 158
High-Capacity Adenoviral Vectors: Expanding the Scope of Gene Therapy
Ricobaraza, A., González-Aparicio, M., Mora-Jimenez, L., Lumbreras, S., & Hernández-Alcoceba, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103643 · Cited by 155
Immunogenicity of CRISPR therapeutics—Critical considerations for clinical translation
Ewaisha, R., & Anderson, K. S. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1138596 · Cited by 153
CRISPR-Cas-mediated transcriptional modulation: The therapeutic promises of CRISPRa and CRISPRi
Bendixen, L., Jensen, T. I., & Bak, R. O. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.03.024 · Cited by 150
Non-viral delivery of the CRISPR/Cas system: DNA versus RNA versus RNP
Lin, Y., Wagner, E., & Lächelt, U. (2022) · Biomaterials Science · doi:10.1039/d1bm01658j · Cited by 148
RNA‐based medicine: from molecular mechanisms to therapy
Sparmann, A., & Vogel, J. (2023) · The EMBO Journal · doi:10.15252/embj.2023114760 · Cited by 151
Nanoparticles for nucleic acid delivery: Applications in cancer immunotherapy
Mukalel, A. J., Riley, R., Zhang, R., & Mitchell, M. J. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.04.040 · Cited by 143
Advances in CRISPR/Cas-based Gene Therapy in Human Genetic Diseases
Wu, S., Li, Q.-C., Yin, C., Xue, W., & Song, C. (2020) · Theranostics · doi:10.7150/thno.43360 · Cited by 145
Wei, T., Cheng, Q., Farbiak, L., Anderson, D. G., Langer, R., & Siegwart, D. J. (2020) · ACS Nano · doi:10.1021/acsnano.0c04707 · Cited by 143
CRISPR/Cas9 gene editing: a new approach for overcoming drug resistance in cancer
Vaghari‐Tabari, M., Hassanpour, P., Sadeghsoltani, F., Malakoti, F., Alemi, F., Qujeq, D., Asemi, Z., & Yousefi, B. (2022) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-022-00348-2 · Cited by 137
Vaidyanathan, S., Salahudeen, A. A., Sellers, Z. M., Bravo, D. T., Choi, S. S., Batish, A., Le, W., Baik, R., Sean de la, O., Kaushik, M. P., et al. (2019) · Cell stem cell · doi:10.1016/j.stem.2019.11.002 · Cited by 135
Self-citationAhmad, M. (2023) · Frontiers in Plant Science · doi:10.3389/fpls.2023.1133036 · Cited by 135
CRISPR/Cas9 systems: Delivery technologies and biomedical applications
Du, Y., Liu, Y., Hu, J., Peng, X., & Liu, Z. (2023) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2023.100854 · Cited by 140
Regulated control of gene therapies by drug-induced splicing
Mas, A., Hundley, A. A., Ranum, P. T., Tecedor, L., Muehlmatt, A., Lim, E., Lukashev, D. E., Sivasankaran, R., & Davidson, B. L. (2021) · Nature · doi:10.1038/s41586-021-03770-2 · Cited by 134
Nanoparticle-Based Delivery of CRISPR/Cas9 Genome-Editing Therapeutics
Givens, B. E., Naguib, Y. W., Geary, S. M., Devor, E. J., & Salem, A. K. (2018) · The AAPS Journal · doi:10.1208/s12248-018-0267-9 · Cited by 133
Therapeutic approaches for Duchenne muscular dystrophy
Roberts, T. C., Wood, M. J. A., & Davies, K. E. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00775-6 · Cited by 134
CRISPR/Cas9 gene-editing: Research technologies, clinical applications and ethical considerations
Memi, F., Ntokou, A., & Papangeli, I. (2018) · Seminars in Perinatology · doi:10.1053/j.semperi.2018.09.003 · Cited by 134
CRISPR/Cas9: Principle, Applications, and Delivery through Extracellular Vesicles
Horodecka, K., & Düchler, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22116072 · Cited by 121
Khoshandam, M., Soltaninejad, H., Mousazadeh, M., Hamidieh, A. A., & Hosseinkhani, S. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2023.02.027 · Cited by 136
Moreno, A. M., Palmer, N. D., Alemán, F., Chen, G., Pla, A., Jiang, N. J., Chew, W. L., Law, M., & Mali, P. (2019) · Nature Biomedical Engineering · doi:10.1038/s41551-019-0431-2 · Cited by 132
Gene-edited stem cells enable CD33-directed immune therapy for myeloid malignancies
Borot, F., Wang, H., Ma, Y., Jafarov, T., Raza, A., Ali, A. M., & Mukherjee, S. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1819992116 · Cited by 131
Clinical delivery of circular RNA: Lessons learned from RNA drug development
Young, T. L., Wang, K. C., Varley, A., & Li, B. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114826 · Cited by 130
The NIH Somatic Cell Genome Editing program
Saha, K., Sontheimer, E. J., Brooks, P. J., Dwinell, M. R., Gersbach, C. A., Liu, D. R., Murray, S. A., Tsai, S. Q., Wilson, R. C., Anderson, D. G., et al. (2021) · Nature · doi:10.1038/s41586-021-03191-1 · Cited by 127
Neumann, E. N., Bertozzi, T. M., Wu, E., Serack, F. E., Harvey, J. W., Brauer, P. P., Pirtle, C. P., Coffey, A. A., Howard, M., Kamath, N., et al. (2024) · Science · doi:10.1126/science.ado7082 · Cited by 129
Lyu, P., Javidi-Parsijani, P., Atala, A., & Lu, B. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz605 · Cited by 123
CRISPR Modeling and Correction of Cardiovascular Disease
Liu, N., & Olson, E. N. (2022) · Circulation Research · doi:10.1161/circresaha.122.320496 · Cited by 120
Precision Control of CRISPR-Cas9 Using Small Molecules and Light
Gangopadhyay, S. A., Cox, K. J., Manna, D., Lim, D., Maji, B., Zhou, Q., & Choudhary, A. (2019) · Biochemistry · doi:10.1021/acs.biochem.8b01202 · Cited by 119
In vitro–transcribed guide RNAs trigger an innate immune response via the RIG-I pathway
Wienert, B., Shin, J. J., Zelin, E., Pestal, K., & Corn, J. E. (2018) · PLoS Biology · doi:10.1371/journal.pbio.2005840 · Cited by 117
Metadata
- Authors
- Charlesworth, C. T., Deshpande, P. S., Dever, D. P., Camarena, J., Lemgart, V. T., Cromer, M. K., Vakulskas, C. A., Collingwood, M. A., Zhang, L., Bode, N. M., Behlke, M. A., Dejene, B., Cieniewicz, B., Romano, R., Lesch, B. J., Gomez-Ospina, N., Mantri, S., Pavel-Dinu, M., Weinberg, K. I., & Porteus, M. H.
- Affiliations
- Stanford Medicine (US)
- Integrated DNA Technologies (United States) (US)
- Corresponding author
- Weinberg, Kenneth I.
- Porteus, Matthew H.
- ORCID
- Charlesworth, Carsten T.
- Dever, Daniel P.
- Camarena, Joab
- Lemgart, Viktor T.
- Cromer, M. Kyle
- Vakulskas, Christopher A.
- Collingwood, Michael A.
- Zhang, Liyang
- Bode, Nicole M.
- Behlke, Mark A.
- Dejene, Beruh
- Cieniewicz, Brandon
- Romano, Rosa
- Lesch, Benjamin J.
- Gomez-Ospina, Natalia
- Mantri, Sruthi
- Pavel-Dinu, Mara
- Weinberg, Kenneth I.
- Porteus, Matthew H.
- Venue
- Nature Medicine
- Published
- 2019-01-28
- Volume
- 25
- Issue
- 2
- Pages
- 249-254
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- PMC
- PMC7199589
- OpenAlex
- W2949380898
- Cited by
- 1,093
- References
- 48
- Citations by year
- 2026: 130 · 2025: 128 · 2024: 132 · 2023: 111 · 2022: 125 · 2021: 166 · 2020: 131 · 2019: 110
- FWCI
- 44.16
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by-nd)
- Funders
- Amon G. Carter Foundation
- National Institutes of Health (5r01ai120766-02)
- National Institute of General Medical Sciences (T32GM119995)
- National Institute of Allergy and Infectious Diseases (R01-AI120766)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA regulation and disease
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Keywords
- CRISPR/Cas9, SaCas9, SpCas9, Staphylococcus aureus, Streptococcus pyogenes, humoral immune response, cell-mediated immunity, genome editing safety
- MeSH terms
- CRISPR-Associated Protein 9, Adult, Cell Separation, Female, Humans, Male, T-Lymphocytes, Adaptive Immunity, Immunity, Humoral
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
